Zai Lab Q3 revenue $69.2M (+22% YoY); launches VYVGART in China, net loss narrows

Third Quarter 2023 Financial Results • Product revenues were $69.2 million for the third quarter of 2023, compared to $57.0 million for the same period in 2022, representing 22% y-o-y growth and 27% y-o-y growth at CER. This increase was primarily driven by increased sales volumes, the launch of VYVGART, and decreased negative effects from the COVID-19 pandemic . Our revenue growth was slowed by the effects on hospital and physician practices from the recent industry-wide anti-corruption enforcement efforts in China. Product revenues in the third quarter of 2023, compared to the same period in 2022, included: – $41.6 million for ZEJULA, which increased from $39.2 million, as ZEJULA, which is in its third year on the NRDL, continued to be the leading PARP inhibitor in hospital sales for ovarian cancer in China; – $11.6 million for Optune, which increased from $10.7 million, supported by increased patient access to this product in the private-pay market; – $5.7 million for QINLOCK, which